Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...

Antibody-Drug Conjugates (ADCs) are a fundamental technology in modern tumor-targeted therapy with their ‘tripartite integrated design’ of ‘precision carrier - stable linker - potent payload’: The ...

The MarketWatch News Department was not involved in the creation of this content. CUSABIO Launches DT3C to Streamline Antibody Screening and Enhance ADC Research HOUSTON, March 7, 2025 ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...

Creative Biolabs provides a one-stop solution from R&D to in vitro evaluation, speeding up ADC projects and satisfying the need for ADC products worldwide. SHIRLEY ...

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

Revvity has launched pHSense™ reagents, a plate-based technology designed to monitor receptor and antibody-drug conjugate (ADC) internalization in high-throughput workflows. The reagents use a ...

In the past ten years, the number of antibody drug conjugate (ADC) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for ...

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: ...

DT3C serves as a novel antibody internalization detection tool that accurately mimics ADC behavior in vitro. This capability enables researchers to assess how efficiently antibodies are internalized ...